FDA added bemotrizinol (Tinosorb S) to US OTC sunscreen: what Korean vs US buyers should know (2026)

TL;DR — On 9 Aug 2026, FDA final order OTC000039 made bemotrizinol (BEMT / Tinosorb S / Parsol Shield) the first new U.S. OTC sunscreen active in 20+ years, at up to 6%. That does not legalize most Korean bottles for U.S. commercial sale: 18-month exclusivity covers DSM (and licensees such as BASF), many common KR companion filters (Tinosorb M / bisoctrizole, Uvinul A Plus, Uvinul T150, Uvasorb HEB, etc.) are still not on the monograph, and U.S. sunscreen remains an OTC drug—not a Korean-style cosmetic.

American shoppers who love K-sunscreens heard "FDA approved Tinosorb S" and assumed Olive Young Global formulas could finally sit on a U.S. drugstore shelf. The order is real. The automatic green light is not. This explainer sticks to what FDA.gov, the order PDF, Korea JoongAng Daily, The Korea Times, and compliance write-ups actually say as of 20 Sep 2026—no invented SPF scores.

Mythbust checklist

Myth	Confirmed reality
"FDA approved Korean sunscreen."	FDA added one active ingredient to OTC Monograph M020. It did not approve SKUs, brands, or Korea's cosmetics pathway.
"Any bottle with bemotrizinol / Tinosorb S is now U.S.-legal."	Only products that meet monograph conditions (concentration, allowed combinations, dosage forms, Drug Facts, etc.) and clear exclusivity / sourcing rules may be commercially marketed as OTC sunscreen drugs.
"Korean shelf formulas = U.S. shelf formulas overnight."	KR formulas commonly stack filters that are still not monograph-listed. Reformulation + U.S. drug compliance is required for legal U.S. retail sale.
"Exclusivity blocks everyone for 18 months, period."	Statute grants 18 months to DSM Nutritional Products LLC (or licensees / assignees / successors). DSM has said BASF holds a sublicense to supply BEMT; Cosmax told JoongAng it already sources DSM and expects its DSM-sourced path to be viable. Broader third-party entry without a license is the late-exclusivity story.
"Import for personal use = selling on Amazon / retail."	Commercial sale in the U.S. requires OTC drug compliance. Personal / cross-border shopping channels are a different risk profile; JoongAng notes customs can still treat noncompliant sunscreens as unapproved drugs. This article is not legal advice.

What FDA actually did (OTC000039)

• Action: Final Administrative Order OTC000039 amends OTC Monograph M020 to add bemotrizinol as a sunscreen active ingredient.
• Announcement / issuance: FDA press announcement dated 9 Jun 2026; Federal Register availability notice and order materials dated 10 Jun 2026 (minor typographical corrections noted 10 Aug 2026 on the order PDF).
• Effective date: ~9 Aug 2026 (order text: August 9, 2026, unless disputed under the statute).
• Concentration: Up to 6% bemotrizinol; finished product must also meet other monograph conditions (including a minimum SPF floor of not less than 2 under the order—not a consumer SPF claim for any brand).
• First in decades: FDA and secondary legal analyses describe this as the first new OTC sunscreen active since the late 1990s / first in more than 20 years, and the first new active added to any OTC monograph via the CARES Act administrative-order process.
• GRASE framing: FDA treats bemotrizinol as generally recognized as safe and effective under the amended monograph conditions for adults and children 6 months and older (agency announcement).
• Dosage forms (high level): Compliant BEMT products may use forms such as oil, lotion, cream, gel, butter, paste, ointment, stick, lipstick, pump spray, or bag-on-valve spray under the order's conditions; propellant-contact aerosol and powder forms were not cleared on the data FDA reviewed for this order (see Venable / Spencer Fane summaries of the final order).

Primary documents: FDA press announcement · OTC000039 final order PDF · Federal Register notice · FDA sunscreen Q&A (mentions OTC000039)

Names you will see on labels and INCI lists

Name	What it is
Bemotrizinol / BEMT	INCI / regulatory name used by FDA
Tinosorb S	BASF trade name (widely used in K-beauty / EU talk)
Parsol Shield	DSM-Firmenich trade name referenced in Korea JoongAng Daily

BEMT itself has been used for years in Korea, Europe, and other markets. The U.S. news is monograph listing, not invention of the molecule.

Exclusivity: why Korean bottles are not automatically U.S.-legal

Section V of OTC000039 implements statutory exclusivity under FD&C Act §505G(b)(5)(C): for 18 months, solely DSM Nutritional Products LLC (or its licensees, assignees, or successors in interest) is authorized to market drugs incorporating the order's changes.

Practical buyer takeaways:

1. Ingredient supply ≠ finished-product free-for-all. During exclusivity, authorized BEMT for U.S. monograph products runs through DSM and licensed suppliers. DSM told Korea JoongAng Daily that BASF has a sublicense to supply BEMT in that window.
2. Clock nuance. DSM told JoongAng the order's effective date is 9 Aug 2026, while the 18-month exclusivity is tied to commercialization and begins when the first FDA drug-listed, monograph-compliant BEMT sunscreen is marketed in the U.S. Compliance explainers (e.g. Axentra) still ballpark broad third-party monograph entry around late 2027 unless a brand licenses or brings its own qualifying data.
3. A Korean bottle that already contains BEMT can still fail if it also contains non-monograph filters, lacks U.S. Drug Facts / listing / establishment registration, or was never built as a U.S. OTC drug.

Filters that still are not on the U.S. monograph (common in KR stacks)

Korea Times and Korea JoongAng Daily both stress that popular Korean formulas often combine BEMT with other modern filters that remain unavailable as FDA-approved sunscreen actives, including:

• Bisoctrizole — Tinosorb M
• Diethylamino hydroxybenzoyl hexyl benzoate — Uvinul A Plus
• Ethylhexyl triazone — Uvinul T150
• Diethylhexyl butamido triazone — Uvasorb HEB
• JoongAng also flags drometrizole trisiloxane as a common companion that is not on the permitted list

Bottom line for shoppers: one new filter does not clone a Korean INCI list into a U.S.-legal Drug Facts panel.

Comparison table: Korea vs United States (buyer lens)

	Korea (typical)	United States (OTC monograph)
Regulatory class	Sunscreen usually regulated as a cosmetic (with local rules / testing)	Sunscreen is an OTC drug under the FD&C Act
How a product reaches market	Cosmetics pathway / MFDS framework for the home market	Must meet OTC Monograph M020 (or an approved NDA/ANDA)—not "cosmetic import then sell"
Bemotrizinol status (as of Sep 2026)	Long-used filter in many formulas	Newly GRASE on monograph via OTC000039, ≤6%, effective ~9 Aug 2026
Other modern filters (Tinosorb M, Uvinul A Plus, etc.)	Common in multi-filter stacks	Still not monograph actives
Labeling shoppers see	Cosmetic-style claims / local labeling	U.S. Drug Facts, directions, warnings; U.S. SPF / broad-spectrum testing methods for compliant products
What "FDA added BEMT" changes for retail shelves	Little direct change to KR domestic SKUs	Opens a path for new U.S.-compliant formulas that use authorized BEMT and only allowed co-actives
Existing KR export bottle on a U.S. store shelf	Designed for KR/global cosmetic markets	Not automatically legal to sell as U.S. sunscreen
Personal cross-border purchase	Shoppers still buy via global malls / Korea shipping (unchanged channels per JoongAng)	Distinct from commercial distribution; noncompliant products can still be treated as unapproved drugs at the border—not legal advice
Who can commercialize BEMT first in the U.S.	OEMs (e.g. Cosmax, Kolmar) preparing U.S.-bound recipes	DSM / licensees during exclusivity; others need license, succession rights, or post-exclusivity / alternate data path

Import / personal use vs commercial sale (sourced distinction)

Commercial sale (U.S. retail, marketplaces as a seller, brand distribution):
Axentra's compliance explainer is blunt: BEMT on the monograph does not mean your Korean or Japanese sunscreen can be sold in the U.S. automatically. You still need the exclusivity/licensing pathway and full OTC drug ops—establishment registration, drug listing / NDC, U.S. Agent (for foreign establishments), Drug Facts labeling, U.S.-method SPF/broad-spectrum testing on the final formula, adverse-event reporting, and so on.

Personal / shopper channels:
Korea JoongAng Daily notes that nothing in the order changed today's consumer channels—global shopping malls and direct purchase from Korea still move Korean-formula sunscreens to U.S. addresses—while stressing that, in FDA's framing, those products can still be treated as drugs that customs can stop. That is a risk and enforcement distinction, not a promise that personal packages are always fine.

If you are a brand: treat "my friends mail me a tube" and "I will list this SKU for sale in the U.S." as different problems.

What this means for buyers (practical)

If you buy in Korea / Olive Young Global / gray-market imports for yourself
Expect the same filter stacks you already know. OTC000039 does not rewrite those bottles. Watch INCI lists if you care about BEMT specifically; many favorites will still list companions that the U.S. monograph does not allow.

If you buy on U.S. shelves / official U.S. brand sites
Look for products that are actually marketed as U.S. OTC sunscreens. Early BEMT launches are expected from parties inside the DSM/licensee supply + drug-compliance pipeline; JoongAng cites manufacturer expectations of meaningful Korean-made U.S.-bound volume later (e.g. Kolmar pointing toward 2H 2027 in its comments to the paper). Do not assume a U.S. listing is the same formula as the Korean twin.

If you formulate or sell
Audit every UV filter against M020, confirm BEMT sourcing against exclusivity, and budget for drug-level labeling/testing/registration—not a sticker swap.

What we are not claiming

• No brand-by-brand SPF "works better" scores, no Consumer Reports-style lab numbers, and no invented water-resistance claims.
• No assertion that personal importation is always lawful or always unlawful—only that commercial sale and personal shopping are treated differently in the sourced coverage.
• No claim that Tinosorb M, Uvinul A Plus, or other KR staples were approved in this order—they were not.
• Pending broader sunscreen monograph proposals (e.g. remnants of the 2021 proposed order OTC000008) may still change labeling/SPF/dosage-form rules later; BEMT's addition does not freeze the rest of sunscreen law.

FAQ

Is bemotrizinol the same as Tinosorb S?

Yes in common industry usage: bemotrizinol (BEMT) is the ingredient; Tinosorb S is BASF's trade name. DSM markets related supply as Parsol Shield (per JoongAng).

When did the U.S. rule take effect?

Final order OTC000039 took effect ~9 Aug 2026, after FDA's June 2026 finalization.

Can I sell my current Korean sunscreen in the U.S. because it already has BEMT?

Not automatically. Exclusivity/licensing, non-monograph co-filters, and U.S. OTC drug requirements still gate commercial sale (Axentra; JoongAng; Korea Times).

Will U.S. "Korean-style" sunscreens feel identical?

Manufacturers quoted by JoongAng argue texture can get closer once BEMT is allowed in U.S.-only recipes—but chemistry will not match KR SKUs that still rely on blocked companions. Treat "same brand, U.S. version" as a different formula until the label proves otherwise.

Is this medical or legal advice?

No. It is a sourced regulatory explainer for shoppers and operators. For commercial plans, use qualified regulatory counsel / a U.S. Agent pathway.

Sources

• FDA — Expands sunscreen options for the first time in 20 years (press announcement, 9 Jun 2026) — https://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years
• FDA — Final Administrative Order OTC000039 PDF (issued 10 Jun 2026; typographical corrections 10 Aug 2026) — https://www.accessdata.fda.gov/drugsatfda_docs/omuf/Order/OTC000039_Final_Administrative_Order.pdf
• Federal Register — Amending OTC Monograph M020; bemotrizinol up to 6% (10 Jun 2026) — https://www.federalregister.gov/documents/2026/06/10/2026-11578/amending-over-the-counter-monograph-m020-sunscreen-drug-products-for-over-the-counter-human-use-and
• FDA — Q&A on OTC sunscreen regulatory actions (includes OTC000039 row) — https://www.fda.gov/drugs/understanding-over-counter-medicines/questions-and-answers-fdas-regulatory-actions-over-counter-sunscreen
• OTC Monographs@FDA order search — https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=ordersearch
• Korea JoongAng Daily — FDA approves bemotrizinol; exclusivity, companion filters, OTC-drug hurdles for K-sunscreen (13 Aug 2026) — https://www.koreajoongangdaily.com/business/is-the-new-us-regulation-an-open-door-or-obstacle-for-ksunscreens/12818291
• The Korea Times — US approves new UV filter; KR multi-filter stacks still not U.S.-compliant (13 Aug 2026) — https://www.koreatimes.co.kr/world/20260813/us-finally-approves-new-uv-filter-can-it-catch-up-with-k-beauty
• Axentra Compliance — Can I import my Korean or Japanese sunscreen into the U.S. now? (exclusivity + OTC drug gates) — https://www.axentracompliance.com/post/import-korean-japanese-sunscreen-into-us-bemotrizinol
• Venable LLP — FDA clears bemotrizinol; first new OTC sunscreen active in 20+ years; exclusivity and dosage-form notes — https://www.venable.com/insights/publications/2026/06/fda-clears-the-way-for-bemotrizinol-first-new-otc
• Spencer Fane — Regulatory exclusivity and commercial implications of OTC000039 — https://www.spencerfane.com/insight/fdas-first-new-sunscreen-active-ingredient-in-decades-regulatory-exclusivity-and-commercial-implications/

---

← Back to all posts